Tom Brady is building a future that stretches far beyond the football field. The NFL legend has backed a major funding round for eMed, a digital healthcare company betting on artificial intelligence to reshape employee wellness. The startup has raised $200 million, pushing its valuation above $2 billion. With Brady investing both money and time, the deal adds a new dimension to his growing business interests.
Tom Brady backs eMed’s $200 million funding round
The latest funding round puts eMed in a new position within the growing digital healthcare market. The Miami-based company secured $200 million in Series A financing, with its valuation now exceeding $2 billion.Brady, who serves as eMed’s founding chief wellness officer, joined a group of prominent investors in the deal. The list includes CEO Linda Yaccarino, former head of X, alongside AON Consulting, Paragon Biosciences founder Jeff Aronin and Valor Equity Partners CEO Antonio Gracias.Other investors include 8VC founder Joe Lonsdale, Chicago Cubs chairman Tom Ricketts and Lettuce Entertain You Restaurants CEO R.J. Melman.For Brady, the investment reflects a personal commitment to the company’s vision. He is not simply lending his name to the venture. His role also connects him with its mission to make healthcare more accessible through technology.“I believe eMed’s empathic agentic AI platform, combined with the strength of its people and partners, represents a true winning formula. That conviction is why I’ve chosen to invest both my time as founding chief wellness officer and my capital in the company,” Brady said in a statement.
How eMed plans to use AI to expand healthcare access
eMed focuses on employee health benefits, offering access to GLP-1 medications, at-home blood testing and ongoing clinical support. Its programmes aim to help employers provide structured care, including support for common side effects associated with GLP-1 treatments.The new funding will help eMed improve its agentic AI platform and prepare for a new capitated care model. The approach is designed to help employers expand access to GLP-1 medications while managing healthcare costs.The company’s focus on AI-powered care also places Brady in a sector where technology and preventive health are increasingly connected. However, eMed’s expansion will depend on how effectively it delivers clinical support while meeting the needs of employers and patients.Brady already has experience in the wellness industry through TB12, his health and fitness company, which offers coaching, training guidance, nutrition and recovery products.His latest investment signals a broader interest in healthcare innovation. As eMed works to scale its platform, Brady’s involvement could help bring more attention to its approach. The $200 million raise gives the company fresh capital, but its long-term impact will depend on how well it turns that investment into accessible, clinically supported care.
